Gene · 5739
Papers1,202
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,202
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension. | Ther Adv Respir Dis | 2026 | 42808704 | PubTator, text mining | PubMed |
| Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review. | Rev Cardiovasc Med | 2026 | 42238623 | PubTator, text mining | PubMed |
| Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children. | BMC Pediatr | 2026 | 42104335 | PubTator, text mining | PubMed |
| Prostaglandin I2 receptor activation promotes alveolar regeneration via the JUN/p53 pathway. | Am J Respir Crit Care Med | 2026 | 42085259 | PubTator, text mining | PubMed |
| Practical Considerations for Managing Transitions from Parenteral Prostacyclins to Oral Selexipag in Pulmonary Arterial Hypertension. | Pulm Ther | 2026 | 41952024 | PubTator, text mining | PubMed |
| Future Prospects of Imatinib in Advanced Pulmonary Hypertension Management. | IUBMB Life | 2026 | 41885124 | PubTator, text mining | PubMed |
| PAH-former: Transfer learning for efficient discovery of pulmonary arterial hypertension-associated genes. | PLoS One | 2026 | 41790620 | PubTator, text mining | PubMed |
| Regulatory roles of bioactive lipids in vascular homeostasis and remodeling. | Med Rev (2021) | 2026 | 41783891 | PubTator, text mining | PubMed |
| Development of immune-derived molecular markers for coronary heart disease via multimachine learning. | iScience | 2026 | 41782820 | PubTator, text mining | PubMed |
| The Pathophysiology, Mechanism, Diagnosis, and Management of Pulmonary Arterial Hypertension: A Comprehensive Literature Review. | US Cardiol | 2026 | 41766785 | PubTator, text mining | PubMed |
| Real-world Persistence on Selexipag for Pulmonary Arterial Hypertension in Canada. | CJC Open | 2026 | 41766702 | PubTator, text mining | PubMed |
| Mechanistic basis for the antifibrotic actions of cAMP-based therapies. | Eur Respir Rev | 2026 | 41708123 | PubTator, text mining | PubMed |
| Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons. | Eur Respir Rev | 2026 | 41708122 | PubTator, text mining | PubMed |
| Efficacy and Safety of Selexipag in Pulmonary Hypertension: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Cardiol Rev | 2026 | 41703674 | PubTator, text mining | PubMed |
| Multiomic analysis of colorectal adenocarcinoma reveals a new subtype of myofibroblastic cancer-associated fibroblasts that express high levels of B7-H3 and have poor-prognosis value. | J Immunother Cancer | 2026 | 41629132 | PubTator, text mining | PubMed |
| Methamphetamine-Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management. | Pulm Circ | 2026 | 41567751 | PubTator, text mining | PubMed |
Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Center Study? | Anatol J Cardiol | 2026 | 41524392 | PubTator, text mining | PubMed |
| Reply. | J Vasc Surg Venous Lymphat Disord | 2026 | 41519514 | PubTator, text mining | PubMed |
Setting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertension (PAH). | Pulm Pharmacol Ther | 2026 | 41519430 | PubTator, text mining | PubMed |
A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension. | Chest | 2026 | 41429287 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5739/papers